-
- Kyowa Hakko Bio Receives FDA No Question Letter For GRAS Notices on Human Milk Oligosaccharides（226KB）
- Kyowa Hakko Bio’s 2’-fucosyllactose received positive EFSA Opinion（262KB）
- Kyowa Hakko Bio Receives EcoVadis Silver Sustainability Rating（119KB）
- Kyowa Hakko Bio’s 6’-sialyllactose is approved as a novel food in EU（246KB）
- Kyowa Hakko Bio’s 3’-sialyllactose received positive EFSA Opinion（244KB）
- Kyowa Hakko Bio’s 6’-sialyllactose received positive EFSA Opinion（252KB）
- Manufacturing strains of Kyowa Hakko Bio’s 3'-sialyllactose and 6’-sialyllactose, human milk oligosaccharides (HMOs), passed safety evaluation in China.（201KB）
- Manufacturing strain of Kyowa Hakko Bio’s 2'-fucosyllactose, a human milk oligosaccharide (HMO), passed safety evaluation in China（395KB）
- Notice Regarding Change of President CEO at Kyowa Hakko Bio（170KB）
- New Research Suggests Citicoline Aids in Memory Function（1.1MB）
- World's first! Kirin Holdings Discovers Memory Benefits from β-Lactolin（884KB）
- Boosting Your Brain : Expansion of Citicoline production facilities at Kyowa Hakko Bio（611KB）
- Kyowa Hakko Bio to Boost Sustainability Through Renewable Energy Certificates at its Strategic Hub in Thailand Reducing GHG emissions from electric power consumption by about 25%（183KB）
- HMO manufacturing facility in Thailand（231KB）
- Notice of Change in Parent Company（68KB）
